Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj